TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01916720

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Study Drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Study Drug
Study: NCT04048928

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: maximal strength training
Description: The training group (TG) performed MST training carried out as free-barbell squats twice a week over five weeks.
Study: NCT01704378

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: biphasic insulin aspart
Description: Individually adjusted dose. Injected subcutaneously (s.c., under the skin) twice daily before breakfast and evening meal
Study: NCT01466647

Intervention type: DRUG
Group type: OTHER
Intervention: AXL1717
Description: A repeated BID treatment for 14 days, followed by a 7 day observation period for two treatment periods
Study: NCT03839979

Intervention type: DIAGNOSTIC_TEST
Intervention: BIOLINE HCV kits
Description: We used BIOLINE HCV kits to detect the presence of HCV antibodies in stick blood samples of all recruited patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: BIOLINE HCV kits
Description: We used BIOLINE HCV kits to detect the presence of HCV antibodies in stick blood samples of all recruited patients.

Intervention type: DIAGNOSTIC_TEST
Intervention: ACCU-CHEK kits
Description: For all patients, we measured random blood sugar levels by stick blood samples using ACCU-CHEK kits.
Study: NCT01153672

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: anastrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exemestane
Description: Given PO

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Correlative studies
Study: NCT02163772

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intracordal hyaluronate injection
Study: NCT02795455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Interoceptive Exposure (IE)
Description: Participants are provided with a meal replacement shake of 'unknown' Kcal or macronutrient content and are asked to mindfully observe the sensations (aversive taste, texture, bloating, icky feeling, etc.) and associated emotional states (i.e., disgust) with the empathetic support of parents/therapist in session, without expectation of habituation. Sessions occur on a weekly basis with session one lasting 2 hrs. The remaining 5 sessions last one hour, and participants eat a meal replacement shake over 30-minutes, identical to the first session. All sessions include debriefing and development of IE homework that includes daily practice of IE.
Study: NCT03839979

Intervention type: DIAGNOSTIC_TEST
Intervention: ACCU-CHEK kits
Description: For all patients, we measured random blood sugar levels by stick blood samples using ACCU-CHEK kits.
Study: NCT02795455

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Family Based Therapy-Weight Gain Control (FBT-WG)
Description: Participants and families randomized to FBT-WG will receive 6-weeks of FBT treatment for AN. Sessions occur weekly, with the first session lasting two hours and the remaining 5 sessions one hour. FBT is atheoretical in terms of the etiology, but uses parent-enforced contingencies to increase value of eating and decrease the value of food avoidance.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: meal replacement shake
Study: NCT03828500

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Assistant-encouraged fasting up to ASA/CAS guideline limits
Description: Research Assistant encourages patient to drink clear fluids up to 2 hour limit before surgery, in accordance with the latest ASA and CAS guidelines.
Study: NCT00905372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2062430
Description: 400 mg intravenously (IV) every 4 weeks for 80 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: intravenously (IV) every 4 weeks for 80 weeks
Study: NCT04163913

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Change in User interfaces of Cirvo compression device application.
Description: Comparison of 2 versions of the Circo user interface

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in User interfaces of Cirvo compression device application.
Description: Comparison of 2 versions of the Circo user interface

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Change in Satisfaction in use of Cirvo device
Description: Comparison of how satisfied patients are with the Cirvo device to a different compression device (ActiveCare)
Study: NCT03839979

Intervention type: DIAGNOSTIC_TEST
Intervention: ErKameter 3000 mercury manometer
Description: For all patients, we measured systolic blood pressure using ErKameter 3000 mercury manometer.

Intervention type: DIAGNOSTIC_TEST
Intervention: ErKameter 3000 mercury manometer
Description: For all patients, we measured systolic blood pressure using ErKameter 3000 mercury manometer.
Study: NCT02216734

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mother support groups for HIV+ mothers
Description: Facility-based mother support groups (MSGs) for HIV+ mothers. MSGs were established prior to study enrolment. MSGs are facilitated by volunteer mothers. Groups meet every two weeks. Health information is provided by health workers during MSGs. Mothers receive HIV prevention, psychosocial and treatment support, reinforce safe feeding practices, promote linkages with family planning services and support disclosure by HIV+ mothers to partners, male attendance and male HIV treatment. Mothers leave MSGs 6 months postnatally. Volunteer MSG coordinators contact defaulting mothers visits using cell phones; VHWs may conduct home visits to to defaulting MSG members to reduce LTFU;
Study: NCT03806790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LEO 90100 foam
Description: Once daily topical application of foam from a can to psoriasis lesions. Dose depends on size of lesion.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dovobet® ointment
Description: Once daily topical application of ointment from a tube to psoriasis lesions. Dose depends on size of lesion.
Study: NCT03280498

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Intubation
Description: elective surgeries under general anesthesia with endotracheal entubation formula or USG asisted
Study: NCT04163913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Change in Satisfaction in use of Cirvo device
Description: Comparison of how satisfied patients are with the Cirvo device to a different compression device (ActiveCare)
Study: NCT02074904

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topiramate
Study: NCT04829643

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MRI
Description: A consecutive cohort of 247 patients with early BC and no suspicious nodes at both clinical and A-US evaluations and candidates to upfront surgery and SNB will be recruited
Study: NCT02074904

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02299804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levophencynonate Hydrochloric
Description: this drug is M receptor inhibitor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levophencynonate Hydrochloric
Description: this drug is M receptor inhibitor

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: No active ingredient
Study: NCT04812860

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18042
Description: Tablet, Dosing frequency: once daily, Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18042
Description: Tablet,Dosing frequency: once daily, Route of administration: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HR18042
Description: Tablet,Dosing frequency: once daily, Route of administration: oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tramadol hydrochloride ER
Description: Tablet,Dosing frequency: once daily, Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tablet,Dosing frequency: once daily, Route of administration: oral
Study: NCT01105949

Intervention type: DEVICE
Group type: OTHER
Intervention: Marketed nasal strip
Description: Marketed nasal strip

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NexGen AB 2R11
Description: Nasal strip prototype

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NexGen JB Organic PET/PE
Description: Nasal strip
Study: NCT00823160

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Sternotomy
Description: Sternotomy performed after finding blood in the pericardial sac

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subxyphoid window
Description: Subxyphoid window performed after the finding of blood in the pericardial sac
Study: NCT05106439

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study competition-related mobile notification
Description: Participants will receive three types of push notifications: 1. Alert of competition type (steps or sleep) and opponent (Sunday 9pm), 2. Competition score status update (Wednesday 9pm, Saturday 11am), and 3. Competition final results (Monday 12pm).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study mobile app
Description: The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study mobile app
Description: The Intern Health Study mobile app is able to conduct a daily mood survey. It also aggregates and visualizes historical data on intern mood, activity, and sleep.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intern Health Study mobile app competition scoreboard and history
Description: Participant can view their current competition scoreboard and competition history at any time via the study app.
Study: NCT00837642

Intervention type: DIAGNOSTIC_TEST
Intervention: Transthoracic echocardiography
Description: Full transthoracic echocardiography will be performed.
Study: NCT04501172

Intervention type: BEHAVIORAL
Intervention: Questionnaire completion
Description: Participants are contacted through social networks (Facebook) which provide a link to website that contains the questionnaire. Then, they complete the questionnaire which consists of the following 2 parts:~1. participant's demographic characteristics with questions regarding age, visual acuity - refractive error, spectacles and contact lenses use, and compliance to mask-wearing directives.~2. 20 items that construct 5 subscales: a) near vision (5 items), b) distance vision (3 items), c) ocular discomfort (3 items), d) driving (2 items), e) limitations (3 items), need for help (2 items), work collaboration (1 item), and emotional impact (1 item).~The impact of spectacles on the compliance of Greek people to mask-wearing directives will be assessed via this questionnaire.
Study: NCT00466661

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: 666 mg po TID
Study: NCT04568473

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRG Barrier Coat (By SHOFU Inc., Japan)
Description: PRG Barrier Coat (By SHOFU Inc., Japan) is a bioactive, resin-based varnish based on the proprietary Giomer concept which incorporates the patented bioactive S-PRG (Surface Pre-Reacted Glass ionomer) filler technology, where a unique combination of six beneficial ions are actively gradually released to provide a smart solution to revolutionize dentin hypersensitivity protocol

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: EMBRACE™ Varnish by (Pulpdent Corporation, USA)
Description: 5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release and it is considered as a novel method of delivering remineralizing ions (Calcium and Phosphate) in combination with xylitol. The incorporation of CXP™ in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish.it has ten times more fluoride release over a 4-hour period than the leading varnish brand, in addition, it also releases bioavailable calcium and phosphate ions which are nano-coated with xylitol.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: EMBRACE™ Varnish by (Pulpdent Corporation, USA)
Description: 5% sodium fluoride with CXP™ (Xylitol-coated Calcium and Phosphate) technology for unsurpassed fluoride release and it is considered as a novel method of delivering remineralizing ions (Calcium and Phosphate) in combination with xylitol. The incorporation of CXP™ in a permeable resin matrix that does not separate, purportedly drives the sustained, time-released properties of this varnish.it has ten times more fluoride release over a 4-hour period than the leading varnish brand, in addition, it also releases bioavailable calcium and phosphate ions which are nano-coated with xylitol.
Study: NCT02451332

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: inactivated seasonal flu vaccine
Description: Women will receive the flu vaccine, and have capillary blood spots collected on day 0 and day 3.
Study: NCT04149106

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine pyrimethamine + Amodiaquin
Description: Monthly dose of SPAQ over three days for SMC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sulfadoxine pyrimethamine + Amodiaquin
Description: Monthly dose of SPAQ over three days for SMC

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin piperaquin
Description: Monthly dose of DHAPQ for SMC
Study: NCT00466661

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 tabs po TID
Study: NCT02069704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab biosimilar (BEVZ92)
Description: Active ingredient Bevacizumab 25 mg/mL (strength = 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to chemotherapy (Folfox any or Folfiri).~FOLFIRI = Folinic Acid + Fluorouracil + Irinotecan FOLFOX = Folinic Acid + Fluorouracil + Oxaliplatin Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If it is well tolerated, the second infusion can be given over 60 minutes. If it is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Avastin® (bevacizumab, reference product)
Description: Active ingredient: Bevacizumab 25 mg/mL (strength: 100 mg/4 mL). 30-minute\* IV infusion (5 mg/kg) every 2 weeks, prior to administration of chemotherapy. Treatment will continue until disease progression, unacceptable toxicity, patient withdraws consent or death (whichever occurs first).~\*The first infusion will be given over 90 minutes. If the first infusion is well tolerated, the second infusion can be given over 60 minutes. If this infusion is well tolerated, subsequent infusions can be given over 30 minutes.~The FOLFOX (any) or FOLFIRI regimen will be chosen as per investigator's criteria based on the hospital standard of care.
Study: NCT03476434

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: chromoendoscopy with indigo carmine
Description: the lumen of the colon is sprayed in a segmental fashion using 0.4% indigo carmine delivered via a specially designed dye spray catheter (Olympus PW-5V1) or via the accessory channel with a 50cc syringe filled with indigo carmine and air.
Study: NCT03949621

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vedolizumab SC
Description: Vedolizumab SC liquid.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vedolizumab SC
Description: Vedolizumab SC liquid.
Study: NCT02448017

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: The Herbst appliance
Description: Orthodontic functional appliance

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Twin block appliance
Description: Orthodontic functional appliance
Study: NCT03622541

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib 200mg
Description: Sorafenib is a multi-kinase inhibitor which is FDA approved for the treatment of metastatic hepatocellular and renal cell carcinomas.
Study: NCT03046563

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Acupressure and Abdominal Massage
Description: Pressing the Hegu (LI 4), Zusanli (ST 36) , Tianshu(ST 25) and abdominal massage for eight minutes

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Pressing the Sham points
Description: Pressing the sham points for eight minutes
Study: NCT04443894

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: PECS block
Description: PECS block is performed at the side of surgery (II) before incision with ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: local infiltration
Description: local infiltration of the surgical wound before incision with πwith ropivacaine 0,375%.(30 ml). General anesthesia is induced and maintained with midazolam, fentanyl, propofol and rocuronium. Pain is assessed postoperatively according to protocol (24 hours and after 3 months).
Study: NCT01964729

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The participants will be randomized into placebo-sham or rTMS or treatment groups for 10 consecutive sessions, at 10 Hz frequency.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham rTMS
Description: Sham Comparator: For the placebo-controlled condition, we will use the same TMS equipment coupled with a placebo coil that produces the same active sound produced by the active coil.
Study: NCT00083304

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Efaproxiral
Description: 75 mg/kg, administered over 30 minutes via a central venous access device (CVAD).~Administered 30 minutes prior to the start of whole brain radiation therapy (WBRT) on each WBRT treatment day for 10 days.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Whole Brain Radiation Therapy (WBRT)
Description: 3.0 Gy per day for 10 days (30.0 Gy total) of WBRT.

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole Brain Radiation Therapy (WBRT)
Description: 3.0 Gy per day for 10 days (30.0 Gy total) of WBRT.
Study: NCT00052481

Intervention type: PROCEDURE
Intervention: quality-of-life assessment
Study: NCT02920372

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EPOETIN ALFA
Study: NCT01257087

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
Study: NCT00083304

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supplemental Oxygen
Description: 4 L/minute by nasal cannula.~Administered at least 35 minutes prior to WBRT, during WBRT and until 15 minutes after completion of WBRT on all WBRT treatment days.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Supplemental Oxygen
Description: 4 L/minute by nasal cannula.~Administered at least 35 minutes prior to WBRT, during WBRT and until 15 minutes after completion of WBRT on all WBRT treatment days.
Study: NCT04569617

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training - UL endurance protocol
Description: UL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
Study: NCT01257087

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: All patients will be prescribed insulin glargine once a day. The dose of the insulin will be adjusted to achieve fasting capillary glucose levels between 5-7 in the intensive group and 7-9 mmol/l in the control group.
Study: NCT02158403

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical Management Recommendations for reducing pump thrombosis
Description: Clinical Management Recommendations for reducing pump thrombosis
Study: NCT04575116

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis free acid tablet
Description: 12.2 mg tafamidis free acid tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis free acid tablet
Description: 12.2 mg tafamidis free acid tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine capsule
Description: 20 mg tafamidis meglumine soft gelatin capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis meglumine capsule
Description: 20 mg tafamidis meglumine soft gelatin capsule
Study: NCT04569617

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training - UL strength protocol
Description: UL strength protocol - 2 series of 8 repetitions, elbow flexion at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
Study: NCT02575937

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low glycemic diet
Description: nutrition education-based low glycemic diet intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low glycemic diet
Description: nutrition education-based low glycemic diet intervention

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: low glycemic diet
Description: nutrition education-based low glycemic diet intervention
Study: NCT04569617

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training - LL endurance protocol
Description: LL endurance protocol - 2 series of 20 repetitions, elbow flexion at 40% of the maximum test strength of 1 maximum repetition, (recovery 1 minutes between sets).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Resistance Training - LL strength protocol
Description: LL strength protocol - 2 series of 8 repetitions, knee extension at 80% of the maximum test force of 1 maximum repetition, (recovery 1 minutes between sets).
Study: NCT01813968

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ischemic postconditioning
Study: NCT03859804

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard transrectal 12 core biopsy
Description: TRUS-guided SPB was performed by obtaining 12 core samples in each patient. 6 cores from left and right. the cores labeled as, apex, mid, base, apex far lateral, mid far lateral and base far lateral

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRI- US fusion prostate biopsy (FPB)
Description: FPB was performed by obtaining 10-12 core samples in each patient, followed by the acquisition of 2-4 core samples for each suspected lesion detected on MpMRI (combined biopsy)